Ocular Therapeutix Inc Share Price Today: Live Updates & Key Insights

Ocular Therapeutix Inc share price today is $8.21, up -1.09%. The stock opened at $8.295 against the previous close of $8.27, with an intraday high of $8.41 and low of $8.04.

Ocular Therapeutix Inc Share Price Chart

Ocular Therapeutix Inc

us-stock
To Invest in {{usstockname}}
us-stock

Ocular Therapeutix Inc Share Price Performance

$8.21 -0.0109(-1.09%) OCUL at 23 Mar 2026 02:35 PM Biotechnology
Lowest Today 8.04
Highest Today 8.41
Today’s Open 8.295
Prev. Close 8.27
52 Week High 16.44
52 Week Low 5.80
Day’s Range: Low 8.04 High 8.41
52-Week Range: Low 5.80 High 16.44
1 day return -
1 Week return -5.04
1 month return -2.79
3 month return -36.95
6 month return -32.89
1 year return +7.56
3 year return +68.83
5 year return -58.95
10 year return -

Ocular Therapeutix Inc Institutional Holdings

FMR Inc 14.60

Fidelity Growth Compy Commingled Pl S 5.83

Deep Track Capital, LP 5.48

Vanguard Group Inc 5.32

SUMMER ROAD LLC 5.10

venBio Select Advisor LLC 4.95

BlackRock Inc 4.85

Fidelity Growth Company Fund 4.32

VR Adviser, LLC 3.36

Vanguard Total Stock Mkt Idx Inv 2.98

TCG Crossover Management, LLC 2.81

Adage Capital Partners Gp LLC 2.12

Point72 Asset Management, L.P. 2.11

iShares Russell 2000 ETF 2.08

Geode Capital Management, LLC 2.00

State Street Corp 1.59

AllianceBernstein L.P. 1.57

Logos Global Management LP 1.49

Millennium Management LLC 1.47

Paradigm Biocapital Advisors LP 1.35

Fidelity Growth Company K6 1.21

Octagon Capital Advisors LP 1.21

Fidelity Series Growth Company 1.16

Deltec Asset Management LLC 1.14

Citadel Advisors Llc 1.14

Morgan Stanley - Brokerage Accounts 1.13

Vanguard Institutional Extnd Mkt Idx Tr 0.85

Fidelity Small Cap Index 0.84

iShares Russell 2000 Growth ETF 0.71

Fidelity Select Pharmaceuticals Port 0.61

AB Small Cap Growth A 0.53

State St Russell Sm/Mid Cp® Indx SL Cl I 0.50

Invesco Pharmaceuticals ETF 0.43

AB Discovery Growth A 0.42

Fidelity Extended Market Index 0.41

Vanguard Russell 2000 ETF 0.41

Candriam Eqs L Biotech C USD Cap 0.39

Schwab US Small-Cap ETF™ 0.38

Fidelity Select Biotechnology 0.36

Janus Henderson Hrzn Biotec E2 USD 0.36

Ocular Therapeutix Inc Market Status

Strong Buy: 6

Buy: 6

Hold: 0

Sell: 0

Strong Sell: 0

Ocular Therapeutix Inc Fundamentals

Market Cap 1780.72 M

PB Ratio 2.7215

PE Ratio 0.0

Enterprise Value 1120.63 M

Total Assets 808.06 M

Volume 4158496

Ocular Therapeutix Inc Company Financials

Annual Revenue FY25:51823000 51.8M, FY23:57717000 57.7M, FY22:51494000 51.5M, FY21:43522000 43.5M, FY20:17403000 17.4M

Annual Profit FY25:45249000 45.2M, FY23:52810000 52.8M, FY22:46954000 47.0M, FY21:39116000 39.1M, FY20:15320000 15.3M

Annual Net worth FY25:-265939000 -265.9M, FY23:-67058000 -67.1M, FY22:-63422000 -63.4M, FY21:-10804000 -10.8M, FY20:-159631000 -159.6M

Quarterly Revenue Q4/2025:13250000 13.3M, Q3/2025:14544000 14.5M, Q2/2025:13459000 13.5M, Q1/2025:10698000 10.7M, Q3/2024:15425000 15.4M

Quarterly Profit Q4/2025:11656000 11.7M, Q3/2025:12770000 12.8M, Q2/2025:11515000 11.5M, Q1/2025:9436000 9.4M, Q3/2024:13864000 13.9M

Quarterly Net worth Q4/2025:-64654000 -64.7M, Q3/2025:-69418000 -69.4M, Q2/2025:-67814000 -67.8M, Q1/2025:-64053000 -64.1M, Q3/2024:-36493000 -36.5M

About Ocular Therapeutix Inc & investment objective

Company Information Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and non-proliferative diabetic retinopathy; OTX-TIC, a travoprost intracameral hydrogel, which has completed phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

Organisation Biotechnology

Employees 325

Industry Biotechnology

CEO Dr. Pravin U. Dugel M.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Ocular Therapeutix Inc FAQs

What is the share price of Ocular Therapeutix Inc today?

The current share price of Ocular Therapeutix Inc is $8.21.

Can I buy Ocular Therapeutix Inc shares in India?

Yes, Indian investors can buy Ocular Therapeutix Inc shares by opening an international trading and demat account with Motilal Oswal.

How to buy Ocular Therapeutix Inc shares in India?

You can easily invest in Ocular Therapeutix Inc shares from India by:

Can I buy fractional shares of Ocular Therapeutix Inc?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Ocular Therapeutix Inc?

Ocular Therapeutix Inc has a market cap of $1780.72 M.

In which sector does Ocular Therapeutix Inc belong?

Ocular Therapeutix Inc operates in the Biotechnology sector.

What documents are required to invest in Ocular Therapeutix Inc stocks?

To invest, you typically need:

What is the PE and PB ratio of Ocular Therapeutix Inc?

The PE ratio of Ocular Therapeutix Inc is N/A and the PB ratio is 2.72.